Since CD133 overexpression is also found in different tumors, the study performed on sarcoma model can be transferable to treatment of all solid tumors expressing CD133 (Smith et al., 2008; Waldron et al., 2011; Bostad et al., 2013). Here, PROM1 is linked to sarcoma.